Published on 22/12/2025
Case Study: Blockchain Implementation in a Multi-Site Clinical Trial
Background and Study Objectives
In 2024, a leading sponsor initiated a blockchain pilot in a Phase III multi-site oncology study spanning 24 global sites across North America, Europe, and Asia. The goal was to assess the feasibility and regulatory acceptability of a blockchain-powered trial master file (TMF), eConsent tracking, and CRA monitoring logs.
The sponsor faced previous audit findings related to delayed site reporting, inconsistent protocol version usage, and missing source data verification (SDV) records. Blockchain was explored as a means to:
- Ensure immutable audit trails
- Enable version control across sites
- Increase CRA accountability and transparency
Blockchain Platform and Architecture
A permissioned Hyperledger Fabric blockchain was selected for the pilot. The platform integrated with the EDC, eTMF, and eConsent systems through secure APIs. Key elements included:
- Data Nodes: Hosted on sponsor, CRO, and three site servers
- Smart Contracts: For auto-logging protocol acknowledgements and consent updates
- Dashboard: Real-time monitoring interface for
Blockchain blocks recorded the following clinical actions:
- Subject eConsent with version and timestamp
- Site acknowledgment of protocol amendments
- CRA SDV visits and report submissions
- SAE logging and escalation
Phase 1: Site Onboarding and Consent Management
The onboarding of 24 sites included blockchain training, ICH E6(R3) compliance review, and system validation documentation distribution. The first major use case deployed was eConsent:
- Each subject’s consent was hashed and stored on-chain
- Subjects could access their consent record via a secure dashboard
- Sites received alerts if a subject tried to consent using an outdated version
Within 2 months, 97% of subjects were onboarded using blockchain-based eConsent. Three subjects who initially signed an old version were flagged in real time and re-consented immediately.
Sample Consent Entry Stored in Blockchain
| Subject ID | Consent Version | Signed Date | PI Approval | Blockchain Hash |
|---|---|---|---|---|
| SUBJ-102 | ICF v4.0 | 2024-11-03 | Dr. Linda Ray | a7f39c0d…de4b9a |
| SUBJ-115 | ICF v3.2 | 2024-11-08 | Dr. Omar Singh | b2d9147e…29ef00 |
Phase 2: CRA Monitoring and Protocol Version Control
In the second phase of the blockchain pilot, CRA monitoring activities were captured and tracked on-chain to ensure:
- Timely submission of site visit reports
- Real-time alerts for overdue SDV
- Immutable records of protocol version usage
Smart contracts automatically notified CRAs of protocol updates. When a CRA acknowledged receipt and trained the site, a blockchain entry was recorded. This ensured full traceability of protocol version control—a common audit finding in the past.
The sponsor also identified that two sites had mistakenly continued using v3.0 of the protocol after v4.1 had been issued. The blockchain record helped demonstrate the sites’ prompt correction and saved the study from a major deviation classification.
Audit Outcome: Blockchain in Regulatory Inspection
During a routine sponsor quality assurance audit and subsequent FDA inspection, the blockchain ledger was used to demonstrate:
- Timely consent and re-consent with timestamp verification
- Continuous protocol version control across all 24 sites
- CRA visit scheduling, execution, and reporting logs
- Unaltered SAE submission timelines
Auditors accessed a blockchain read-only dashboard where they validated hash integrity, cross-checked protocol versions per site, and verified eConsent sequence. The sponsor received a positive inspection report, specifically citing “impressive use of blockchain to ensure audit readiness and protocol compliance.”
Challenges Faced During the Pilot
- Training site staff on blockchain dashboard access and terminology
- Integration lag between eTMF and the blockchain node
- Local IRB hesitancy in approving consent data hashing
These were mitigated through additional SOPs, site-specific change controls, and IRB consultation using a EMA-aligned justification on data minimization and encryption.
Benefits Observed from the Pilot
- 36% faster CRA close-out due to automated logging
- Zero missing consent or re-consent entries
- 84% reduction in protocol deviation queries
- Improved sponsor-CRO-site trust and transparency
The sponsor plans to roll out blockchain infrastructure for all decentralized trials starting 2026, particularly where multiple CROs or remote consent processes are involved.
Validation and SOP Adaptations
The blockchain system was validated under GAMP5, and SOPs were updated to include:
- Blockchain entry review during monitoring visits
- Ledger hash validation at study closeout
- Role-based access for auditors and inspectors
- System change control log validation
A comprehensive validation package including user requirements, risk assessment, IQ/OQ/PQ, and hash integrity tests was filed in TMF Zone 7 (Central Trial Management Systems).
Conclusion: A Scalable Blueprint for Blockchain in Trials
This case study highlights how blockchain can be successfully piloted across a global multi-site trial to address long-standing GCP compliance issues. Through real-time transparency, automated tracking, and immutable audit trails, blockchain enables more efficient, compliant, and patient-centric trials.
For blockchain validation templates, CRA monitoring SOPs, and site training material, visit PharmaValidation. For additional implementation case studies, explore PharmaGMP.